tbuckley/cabot-search huggingface dataset:
Descriptive epidemiology of meningiomas in the United States.
Authors: John L. Villano, Stephen Todd Anderson, Therese A. Dolecek
Journal: Journal of Clinical Oncology (2013)

2099 Background: Although meningioma is the most common tumor in the central nervous system (CNS), the incidence, epidemiology, and clinical outcomes have historically been poorly defined. Our analysis follows the implementation of Public Law 107–260, the Benign Brain Tumor Cancer Registries Act mandating collection of non-malignant meningiomas. Methods: Surveillance Epidemiology End Results Program (SEER) 18 registries research data on cases diagnosed during 2004-2009 with meningioma (ICD-O-3 histology codes 9530-9534 &amp; 9537-9539) in brain or CNS primary site (C70.0-72.9, 75.1-75.3 ) were analyzed. Population-based statistics were generated using SEER*Stat 8.0.1 software. Results: A total of 35,302 cases (34,718 non-malignant; 584 malignant) were available providing a rate of 7.18/100,000, with meningioma, NOS (9530/0) the most common histology. Rates increased with age (0.13/100,000, 0-19 years; 37.78/100,000, 75+ years). The annual percentage change in incidence rates showed a statistically significant increase of 2.57% over 2004-2009. Significant increases were also observed for males, females, whites, blacks, non-Hispanics, and older age groups. The gender ratio M:F was 0.35 in the 0-49 age group and 0.48 in the 50+ age. Primary site location included cerebral meninges (83%) with almost 5% in the spinal meninges. 51% of cases were diagnosed pathologically versus imaging. However, diagnosis among 85% of spinal cases was surgically based. Older age and females were less likely to have a surgical diagnosis. 3.4% received radiation therapy (RT) with 97% receiving RT following surgery. For grade III or malignant cases, 22% received RT, and in grade 1 and 2 nearly 97% of cases did not receive RT, with older age groups less likely to receive RT. Overall survival was high, except for grade 3 or malignant cases where 5 year relative survival was 61.7%. Conclusions: Our analysis following Public Law 107–260 demonstrates an increasing incidence of meningiomas and provides new information, including a decrease in the gender difference with age. Clinical diagnosis is common and higher in women and older adults. Use of RT is low, even in malignant meningiomas, and employed following surgery. These observations were similar for white and black cases.
Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis
Authors: M. A. Stroehlein, K. U. Gruetzner, A. Tarabichi, K. W. Jauch, K. Bartelheim, H. Lindhofer, R. Von Roemeling, M. M. Heiss
Journal: Journal of Clinical Oncology (2006)

2544 Background: Peritoneal carcinomatosis (PC) due to GI-tract cancer is an advanced tumor stage with poor survival. At present, no standard therapy has been recommended, as chemotherapy and surgery showed only limited efficacy in affected patients. When applied intraperitoneally (i.p.), the trifunctional antibody catumaxomab could be shown to destroy intraperitoneal tumor cells in patients with malignant ascites due to ovarian cancer. While binding simultaneously to EpCAM (on tumor cells), CD3 (T cells) and, via the Fc region, to Fc gamma receptor 1 and 3 on accessory cells, it induces a complex immunoreaction against epithelial tumor cells. The aim of this study was to investigate clinical efficacy of i.p. catumaxomab therapy in patients with PC compared to a matched control group. Methods: Between 2003 and 2005, 22 patients with PC due to cancer of colon (n=10), stomach (8), pancreas (3) and CUP (1) received treatment with catumaxomab within a phase I study. Treatment consisted of 3 to 4 i.p. applications (10–200 μg) of escalating catumaxomab doses. The survival was compared with patients receiving conventional therapies in a matched-pair analysis regarding sex, age, tumor surgery, chemotherapy, and extent of PC. Patients with existing ileus and clinically significant ascites were not included. Results: Follow up of patients receiving catumaxomab showed a median survival of 12.2 months (range 2–34) after first diagnosis of peritoneal carcinomatosis vs. 9.7 months (range 1–40) in patients with conventional treatment (p=0.005; log-rank). These data will be updated at presentation. Conclusion: Intraperitoneal treatment with the trifunctional antibody catumaxomab may be an attractive option for treatment of patients with peritoneal carcinomatosis due to GI-tract cancer. The convincing results have to be further investigated in clinical phase II/III trials. [Table: see text]
Influence of bevacizumab on early postoperative complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Authors: Clarisse Eveno, Olivier Glehen, Diane Goéré, Anne-Claire Lukaszewicz, Guillaume Passot, Dominique Elias, Marc Pocard
Journal: Journal of Clinical Oncology (2012)

601 Background: Increasingly patients with IV stage colorectal cancer received systemic chemotherapy combined with targeted therapy among which bevacizumab. In neoadjuvant situation, a delay of at least 6 weeks between discontinuation of bevacizumab and surgery is recommended, not to increase the risk of complications (delayed healing, bleeding) related to bevacizumab. The goal of this study was to analyze the potential impact of bevacizumab on early morbidity after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal origin. Methods: From 2004 to 2010, in three hospitals, 183 patients treated with complete cytoreduction followed by HIPEC for colorectal carcinomatosis, received preoperative treatment. It was either systemic chemotherapy alone (Chemo group, n = 100) or by chemotherapy combined with bevacizumab (Beva group, n = 83). Results: Both patient groups were comparable in the extent of carcinomatosis, assessed on peritoneal cancer index means (10.4 vs 10, p&gt; 0.05), number of resected organs (4.3 vs 3.8, p&gt; 0.05), operative time (420 vs. 380 minutes, p&gt; 0.05) and volume of blood loss (470 vs 510ml, p&gt; 0.05). The median time from discontinuation of bevacizumab and HIPEC was 7 weeks (6-10), always greater than 6 weeks. Nine patients postoperatively died, 4 (4%) in the chemo group and 5 (6%) in the beva group (ns). Grade 3 to 5 complication rate was higher in the beva group (25 vs 12%, p &lt;0.05). Whatever the hospital, complications that may be related to bevacizumab occurred more frequently in patients in the beva group: with more digestive fistulas (18 vs 8%, p &lt;0.05), deep abscesses (13 vs 3 %, p &lt;0.01) and delayed healing (11 vs 2%, p &lt;0.02). Conclusions: Administration of bevacizumab before surgery with complete cytoreduction followed by HIPEC for carcinomatosis colorectal is associated with increased morbidity, probably due to multiple organ resections performed during the surgery. The oncologic benefit of bevacizumab before HIPEC remains to be evaluated.
Association of Exposure to Communities With High Obesity With Body Type Norms and Obesity Risk Among Teenagers
Authors: Ashlesha Datar, Amy Mahler, Nancy Nicosia
Journal: JAMA Network Open (2020)

used to correct bias in self-reports and parent-reports using regression calibration.Adolescents were classified as having obesity if this corrected body mass index, calculated as weight in kilograms divided by height in meters squared, was in at least the 95th percentile for their age and sex.Adolescents selected their ideal body type (IBT) on a figure rating scale consisting of 9 figures, matched by their sex, that captured normal body mass index (figures A-C), overweight (figure D), and
ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation
Authors: Juan Manuel Leyva-Castillo, Claire Galand, Shunya Mashiko, Robert Bissonnette, Alex McGurk, Steven F. Ziegler, Chen Dong, Andrew N.J. McKenzie, Marika Sarfati, Raif S. Geha
Journal: Journal of Allergy and Clinical Immunology (2020)

Atopic dermatitis skin lesions demonstrate increased expression of IL-25 by keratinocytes and increased numbers of type 2 innate lymphoid cells (ILC2s) that express high levels of IL-25 receptor (IL-25R). IL-13 is expressed in atopic dermatitis skin lesions and plays an important role in pathogenesis of the disease.Our aim was to determine the role of IL-25 and ILC2s in a mouse model of antigen-driven allergic skin inflammation.Wild-type mice; mice that express an Il13-driven enhanced green fluorescent protein; and mice that lack IL-25R, IL-25 in keratinocytes, or IL-13 or IL-25R in ILC2s were subjected to acute or chronic epicutaneous sensitization with ovalbumin. Sensitized skin was examined by histology for epidermal thickening. Cellular infiltrates were analyzed for surface markers and intracellular expression of enhanced green fluorescent protein by flow cytometry. Gene expression was quantitated by RT quantitative PCR.In both acute and chronic antigen-driven allergic skin inflammation, signaling by keratinocyte-derived IL-25 in ILC2s is important for epidermal hyperplasia, dermal infiltration by CD4+ T cells, and cutaneous expression of Il13 and the IL-13-dependent TH2-cell-attracting chemokines Cc17 and Ccl22. ILCs are the major source of IL-13 in acutely sensitized mouse skin, whereas T cells are its major source in chronically sensitized mouse skin.ILC2 activation by IL-25 is essential for IL-13 expression at sites of allergic skin inflammation.
NONINVASIVE PRESSURE-VOLUME LOOP ANALYSIS DEMONSTRATES CHANGES IN VENTRICULAR CONTRACTILITY, EFFICIENCY AND POWER IN TETRALOGY OF FALLOT AFTER PULMONARY VALVE REPLACEMENT
Authors: Edem Binka, Jin Zhang, Felicia Seemann, Marcus Carlsson, Vivek Jani, Joao A.C. Lima, Bharath Ambale Venkatesh, Benjamin Barnes, Shelby Kutty
Journal: Journal of the American College of Cardiology (2020)
Redesigning safety regulation in the NHS
Authors: Charles Vincent, Eirini Oikonomou, Jane Carthey, Carl Macrae
Journal: BMJ (2020)

Healthcare relies on a variety of regulatory activities to manage risks to the public and to drive improvement.But the regulation of patient safety in healthcare, and in the NHS in particular, is "bewildering in its complexity and prone to both overlaps of remit and gaps between different agencies." 1 Regulatory activities touch every single aspect of care delivery and place considerable demands on professionals and organisations alike, in the form of inspections, certification, accreditation, revalidation, and compliance reporting.We argue that the safety regulatory system, as seen from the perspective of provider organisations, is much larger and more complex than usually supposed.Individual regulators might achieve valuable impact, but the system as a whole is unnecessarily burdensome, produces multiple unintended consequences, and, most importantly, fragments and dilutes regulatory impact.We discuss the nature of these problems and set out a series of practical proposals for tackling these critical challenges. What is regulation?Regulation can be defined as the "processes that aim to shape, motivate, monitor, and modify the practices and technologies within organisations so as to achieve some desired state of affairs." 2 Regulatory activities take many forms, not all of them formal or backed by coercive or legal force. 3The work of regulating patient safety reaches from the "ivory towers" of policy making and standard setting to the "adobe huts" of local participation and frontline decision making. 4gulation is achieved in multiple ways and by many different organisations.Statutory regulators, such as the Care Quality Commission and the General Medical Council, conduct inspections, monitor standards, and carry out a range of other activities.Many other organisations exert a regulatory effect on NHS organisations in the sense of inspecting, monitoring, influencing performance, and other activities (box 1, box 2).Royal colleges, for example, set standards, review training, and influence organisations and individuals through the encouragement and enforcement of professional norms.They also set standards and have the power to impose sanctions, such as withdrawal of approval of training.
INSUFFICIENT CALORIC INTAKE IS ASSOCIATED WITH POOR QUALITY OF LIFE AND READMISSION BURDEN POST-DISCHARGE IN OLDER PATIENTS WITH HEART FAILURE
Authors: Scott L. Hummel, Feriha Bilgen, Peiyu Chen, Hannah Rosenblum, Armella Poggi, Maria L. Cornellier, Tonimarie Catalan, Sergio Teruya, Stephen Helmke, Wahida Karmally, Mathew Maurer
Journal: Journal of the American College of Cardiology (2020)
COMPARING POST MORTEM MAGNETIC RESONANCE IMAGING AND COMPUTED TOMOGRAPHY TO CONVENTIONAL AUTOPSY IN CASES OF SUDDEN UNEXPECTED DEATH
Authors: Giuseppe Femia, Neil Langlois, Jim Raleigh, Belinda Gray, Farrah Othman, Sunthara Rajan Perumal, Christopher Semsarian, Rajesh Puranik
Journal: Journal of the American College of Cardiology (2020)
Has the “ASCO top 5” changed radiologic staging practices among physicians who treat breast cancer?
Authors: Demetrios Simos, Brian Hutton, Dean Fergusson, Mark Clemons
Journal: Journal of Clinical Oncology (2013)

6597 Background: The American Society of Clinical Oncology (ASCO) recently published its "Top 5" list for fiscal responsibility in oncology. One of the recommendations was to minimize imaging tests looking for metastatic disease in patients (pts) with early stage breast cancer (BC). This recommendation is in close agreement with other published guidelines. The objective of this study was to see whether physician practice patterns have changed following the publication of the "ASCO Top 5" list. Methods: A retrospective review of pts with operable early-stage BC seen at a large Canadian cancer centre was performed. All perioperative (pre- &amp; post-operative) imaging ordered to detect distant metastases (e.g. in the chest, abdomen and bones) was captured. Additional data on demographics, surgical procedure, pathology, prognostic/predictive factors and treatment was also collected. Results: 200 pt charts were reviewed: 100 pre- &amp; 100 post- the "ASCO Top 5" publication. Baseline pt and tumor characteristics were similar in both groups. In the Pre-Top 5 group, 83% had at least 1 staging imaging test. The total number of perioperative tests in this group was 293, for an average of 3.53 tests/pt imaged. In the Post-Top 5 group, 84% had at least 1 staging imaging test. The total number of perioperative tests in this group was 320, for an average of 3.81 tests/pt imaged (p=ns). Further imaging to clarify indeterminate perioperative imaging results was required in 51/167 pts imaged (31%). Radiologically evident metastases were found in only 2/200 pts (both stage 3). None of the clarification imaging showed metastatic disease. Conclusions: This study again highlights the very low yield from imaging in early stage BC. Confirmatory imaging was frequent and did not yield additional metastatic disease. Local practice patterns do not appear to be affected by the recent ASCO publication. Further study is needed to determine how to successfully implement the ASCO recommendation, as excessive imaging is cost prohibitive and can lead to unwanted treatment delays and exacerbate pt anxiety.
Abstract 10615: Prognostic Impact of Geriatric Nutritional Risk Index on 3-Year Clinical Outcomes After Percutaneous Coronary Intervention in Hemodialysis Patients
Authors: Keita Koseki
Journal: Circulation (2018)

Introduction: Patients with end-stage renal disease (ESRD) on hemodialysis (HD) has been associated with poor clinical outcome after coronary revascularization. Previous reports showed geriatric nu...
IN VIVO ECHOCARDIOGRAPHIC DEMONSTRATION OF AN INFARCT ZONE IN AN OPEN CHEST PIG MODEL WITH A NOVEL, NESTED PHASE-CHANGE CONTRAST AGENT HAVING AN ACOUSTIC RESPONSE DEPENDENT ON MYOCARDIAL VIABILITY PERFUSION AND DEPOLARIZATION
Authors: Brett Angel, Andrew Kohut, Steve Wrenn, Michael Flynn, Michael Cimorelli, Aaron Fafarman
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION OF ADIPONECTIN WITH RISK OF CARDIOVASCULAR EVENTS AND HEART FAILURE IN OLDER ADULTS: ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
Authors: Lu Xu, Wensheng Sun, Xiaoming Jia, Eric Boerwinkle, Kunihiro Matsushita, Chiadi Ndumele, Elizabeth Selvin, Bing Yu, Christie M. Ballantyne, Ron Hoogeveen
Journal: Journal of the American College of Cardiology (2020)
TB expert is suspended for 12 months for possessing extreme pornography
Authors: Clare Dyer
Journal: BMJ (2020)

A leading lung specialist who was cautioned by police for possessing extreme pornography involving bestiality has been suspended from the UK medical register for 12 months.

Peter Davies, an internationally recognised expert on tuberculosis, viewed images that “portrayed, in an explicit and realistic way, a person performing an act of intercourse with an animal, namely a horse and a dog,” a medical practitioners tribunal heard.

Nine images depicting bestiality were recovered from his computer hard drive at Liverpool Heart and Chest Hospital in December 2018. Davies, 70, was an honorary physician at the hospital after retiring in 2015, …
HIGH RISK PERCUTANEOUS CORONARY REVASCULARIZATION SUPPORTED BY IMPELLA: GOOD OUTCOMES WITH MARKED REDUCTION IN CAD BURDEN DESPITE BEING TURNED DOWN FOR CABG
Authors: Maryna Popp, Debapria Das, Justin D'addario, Elsayed Abo-Salem, Tarek Helmy, Michael J. Lim
Journal: Journal of the American College of Cardiology (2020)
進行非小細胞肺癌における第一選択エルロチニブ化学療法に続く第二選択シスプラチン・ゲムシタビン併用化学療法: TORCH無作為化試験
Authors: Gridelli Cesare, Ciardiello Fortunato, Gallo Giro, Feld Ronald, Butts Charles, Gebbia Vittorio, Maione Paolo, Morgillo Floriana, Genestreti Giovenzio, Favaretto Adolfo, Leighl Natasha, Wierzbicki Rafal, Cinieri Saverio, Alam Yasmin, Siena Salvatore, Tortora Giampaolo, Felletti Raffaella, Riccardi Ferdinando, Mancuso Gianfranco, Rossi Antonio, Cantile Flavia, Tsao Ming-Sound, Saieg Mauro, Santos Gilda da Cunha, Piccirillo Maria Carmela, DI Maio Massimo, Morabito Alessandro, Perrone Francesco
Journal: Journal of Clinical Oncology (2012)
A phase I/II trial of weekly docetaxel and cisplatin for locoregionally recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
Authors: S. Chia, J. J. Laskin, S. D’Aloisio, B. Vinduska, M. Webster, S. B. Kangarloo, D. Hao
Journal: Journal of Clinical Oncology (2006)

15523 Background: Docetaxel and cisplatin are both active agents in the treatment of advanced SCCHN. In phase II trials the combination of docetaxel and cisplatin delivered on a 3 weekly schedule in recurrent/metastatic SCCHN demonstrated response rates (RR) of 33–46%, however it is associated with significant morbidities and treatment related mortalities. In a phase IB trial design we sought to determine the maximal tolerated dose (MTD) and the recommended dose for weekly docetaxel and cisplatin to further study in a phase II trial. Methods: Patients with measurable locoregionally recurrent and/or metastatic SCCHN with no prior chemotherapy for advanced disease were eligible. Four dose levels were planned, starting with docetaxel 25 mg/m 2 and cisplatin 20 mg/m 2 weekly (dose level 1) to docetaxel 35 mg/m 2 and cisplatin 25 mg/m 2 (dose level 4) for three consecutive weeks followed by a one week break (=1 cycle). Pharmacokinetics (PK) were performed during cycle 1 and 2. Response was assessed following every 2 nd cycle. Patients were followed for safety, tolerability, duration of response and survival. Results: 16 patients were enrolled from Aug 2003-Oct 2005. 80% were male, median age 61 years (36–72), median PS 1 (0–2), 30% had prior platinum exposure as a radio-sensitizer, and two-thirds had metastatic SCCHN. MTD was not achieved with dose level 4. Median number of cycles delivered was 3 (1–6) with no significant dose reductions or delays. No G3/4 hematological toxicities or febrile neutropenia was seen across all the dose levels. One G3 dysphagia, one G3 emesis and three G3 metabolic toxicities were seen. There was no treatment related deaths. 1 CR, 2 PR and 7 stable diseases were seen with a median duration of response/stable disease of 3 months (2–19). Conclusions: Combination weekly docetaxel and cisplatin is a well tolerated and active regimen in recurrent/metastatic SCCHN. The recommended dose is docetaxel 35 mg/m 2 and cisplatin 25 mg/m 2 (3 consecutive weeks out of 4) in the planned phase II trial. [Table: see text]
IMPORTANCE OF FOLLOW-UP ECHOCARDIOGRAPHY IN CARDIAC AMYLOIDOSIS: PROGNOSIS ASSOCIATED WITH APICAL STRAIN HAS A LIMITED WARRANTY PERIOD
Authors: Jay Patel, Muzna Hussain, Mazen Hanna, Brian P. Griffin, Grace Karam, Jay Ramchand, Dermot Phelan, Deborah Kwon, Zoran Popovic, Richard A. Grimm, Wael A. Jaber, Paul Cremer, Rory Hachamovitch, Patrick Collier
Journal: Journal of the American College of Cardiology (2020)
In-hospital cancer care: Are we missing an opportunity for end of life care?
Authors: Gabrielle Betty Rocque, Anne Elizabeth Barnett, Lisa Illig, Howard Harry Bailey, Toby Christopher Campbell, James A. Stewart, James F. Cleary
Journal: Journal of Clinical Oncology (2012)

9039 Background: Little data exists on the estimated survival of patients with metastatic cancer after hospitalization. As part of a prospective quality improvement project, we characterized the population of patients admitted to an inpatient oncology service in an academic medical center with emphasis on the disposition at discharge and overall survival. Methods: We collected data over a 4 month period (9/1/10-12/23/10) representing 149 admissions of 119 unique patients. We measured patient characteristics, disease evaluation, procedures, consults, imaging studies performed, disposition, length of stay, and overall survival. These data were compared to a similar study conducted in our center in 2000. Results: Uncontrolled symptoms were the most common reason for admission (pain 28%, dyspnea 9%, nausea 9%). Imaging studies were more common than in 2000 (415 vs. 196 total procedures). Eighty-five percent of patients had progressive disease. Seventy percent of patients were discharged home without additional services such as home health or hospice. The overall median survival was poor in 2000 and in 2010, 100 days and 60 days from discharge, respectively. Despite an overall poor prognosis, palliative care consultation was obtained only 13 times (8% of admissions) and 18% of patients were enrolled in hospice at discharge. Conclusions: An unscheduled hospital admission portends a poor prognosis. Cancer patients in the hospital are nearing the end-of-life with a median life expectancy of approximately 3 months and could be considered hospice-eligible and appropriate for a palliative care consult. We believe that hospital admission represents a missed opportunity to provide palliative care services and end-of-life counseling to this patient population.
A piece of my mind. The 'older' doctor
Authors: J. A. Cowan
Journal: JAMA (1988)

My first practice was with an older doctor. It took me only a few weeks to realize that the man was a buffoon at best, perhaps even incompetent. I had recently completed my training at an academic medical center, and I saw quickly that my older partner wasted valuable time listening to silly things his patients told him, that he failed to order all the tests that were needed to nail down a diagnosis, that he used treatments I knew were years out-of-date. Amazingly, his patients seemed to thrive on his mismanagement. His success was undeniable: after all, he needed me, his new associate, to help out. Nevertheless, I was determined to show him how medicine should be practiced. I settled down to apply all I had learned during my seven years of training. I ordered lots of tests, enough to confirm diagnoses beyond any shadow of a doubt. I